Human psychopharmacology最新文献_第2页

Gender influences on efficacy and safety of sublingual zolpidem tartrate for middle-of-the-night awakening in insomnia. 酒石酸唑吡坦舌下治疗失眠症半夜醒来疗效和安全性的性别影响。

IF 1.7

Human psychopharmacology Pub Date : 2014-01-01 Epub Date: 2013-11-07 DOI: 10.1002/hup.2364

Thomas Roth, Frank Steinberg, Nikhilesh N Singh, Margaret Moline

{"title":"Gender influences on efficacy and safety of sublingual zolpidem tartrate for middle-of-the-night awakening in insomnia.","authors":"Thomas Roth, Frank Steinberg, Nikhilesh N Singh, Margaret Moline","doi":"10.1002/hup.2364","DOIUrl":"https://doi.org/10.1002/hup.2364","url":null,"abstract":"Objective: Evaluate potential gender effects on efficacy and safety of a buffered zolpidem sublingual tablet (ZST) formulation.Methods: Post hoc analysis of the pivotal sleep laboratory and outpatient studies, per gender.Results: In the sleep laboratory study, polysomnography-derived latency to persistent sleep after middle-of-the-night was significantly improved for both genders at both 1.75 mg and 3.5 mg ZST (females: 15.7 and 8.6 min, respectively, vs. 27.7 min [placebo]; males: 19.0 and 12.7 min vs. 29.0 min [placebo]) with no significant gender differences. In the outpatient study, subjective sleep onset latency after middle-of-the-night was significantly shorter for both genders treated with ZST 3.5 mg versus placebo over the 4-week average (females: 37.3 vs. 59.4 min, p < 0.0001; males: 38.6 vs. 55.1 min, p ≤ 0.01). There were no gender differences in subjective sleep onset latency after middle-of-the-night awakening. In the outpatient study, weekly usage of ZST and placebo by both genders declined throughout the study. Morning alertness following dosing nights improved in both genders, although significant only in females. In both studies, there were no gender differences in adverse events.Conclusion(s): Time to return to sleep after middle-of-the-night dosing with ZST improved in both genders, with no gender differences in efficacy and safety.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"25-30"},"PeriodicalIF":1.7,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2364","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32030844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

The effect of attenuating noradrenergic neurotransmission by clonidine on brain activity measures of visuospatial attention. 可乐定减弱去甲肾上腺素能神经传递对视觉空间注意脑活动测量的影响。

IF 1.7

Human psychopharmacology Pub Date : 2014-01-01 DOI: 10.1002/hup.2367

H N Alexander Logemann, Koen B E Böcker, Peter K H Deschamps, Chantal Kemner, J Leon Kenemans

{"title":"The effect of attenuating noradrenergic neurotransmission by clonidine on brain activity measures of visuospatial attention.","authors":"H N Alexander Logemann, Koen B E Böcker, Peter K H Deschamps, Chantal Kemner, J Leon Kenemans","doi":"10.1002/hup.2367","DOIUrl":"https://doi.org/10.1002/hup.2367","url":null,"abstract":"Objective: In the current study, we investigated the role of noradrenaline in directing (bias) and disengagement of visuospatial attention.Methods: We assessed the effect of clonidine on event-related brain potential (ERP) reflections of bias and disengagement in a double-blind placebo-controlled crossover design. An initial dose of 200-μg clonidine was replaced by 100 μg because of marked side effects. Twenty-one healthy male participants performed the visual-spatial cueing task while an electroencephalogram (EEG) was recorded. The behavioral output is the validity effect (benefit of cueing in terms of reaction time to targets). ERP indices for bias were the cue-related early directing attention negativity and late directing attention positivity, and the target-elicited P1 and N1 modulations by validity ('validity-effect'). The ERP index for disengagement was the target-elicited 'late positive deflection' modulation by validity. Behavioral analyses were performed on 16 participants, electrophysiological analyses on a subset (n=9).Results: Clonidine attenuated the N1 effect, albeit in a subsample. Neither cue-elicited ERPs nor the behavioral validity effect were affected. Clonidine-induced blood pressure reduction was correlated with the reduction of the late positive deflection effect under clonidine.Conclusion: Clonidine attenuated the result of bias in a subsample and may have a modulating effect on disengagement.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"46-54"},"PeriodicalIF":1.7,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2367","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31857678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Interleukin 1 beta gene and risk of schizophrenia: detailed case-control and family-based studies and an updated meta-analysis. 白细胞介素1 β基因与精神分裂症的风险:详细的病例对照和基于家庭的研究以及最新的荟萃分析。

IF 1.7

Human psychopharmacology Pub Date : 2014-01-01 DOI: 10.1002/hup.2365

Masako Shibuya, Yuichiro Watanabe, Ayako Nunokawa, Jun Egawa, Naoshi Kaneko, Hirofumi Igeta, Toshiyuki Someya

{"title":"Interleukin 1 beta gene and risk of schizophrenia: detailed case-control and family-based studies and an updated meta-analysis.","authors":"Masako Shibuya, Yuichiro Watanabe, Ayako Nunokawa, Jun Egawa, Naoshi Kaneko, Hirofumi Igeta, Toshiyuki Someya","doi":"10.1002/hup.2365","DOIUrl":"https://doi.org/10.1002/hup.2365","url":null,"abstract":"Objective: Interleukin-1 beta (IL-1β) has been implicated in the pathophysiology of schizophrenia. To assess whether the IL1B gene confers increased susceptibility to schizophrenia, we conducted case-control and family-based studies and an updated meta-analysis.Methods: We tested the association between IL1B and schizophrenia in 1229 case-control and 112 trio samples using 12 markers, including common tagging single nucleotide variations (SNVs) and a rare non-synonymous variation detected by resequencing the coding regions. We also performed a meta-analysis of rs16944 using a total of 8724 case-control and 201 trio samples from 16 independent populations.Results: We found no significant associations between any of the 12 SNVs examined and schizophrenia in either case-control or trio samples. Moreover, our meta-analysis results showed no significant association between the common SNV, rs16944, and schizophrenia.Conclusions: The present study does not support a role for IL1B in schizophrenia susceptibility.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"31-7"},"PeriodicalIF":1.7,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2365","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40262685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. 藏红花治疗氟西汀诱导的女性性功能障碍:随机双盲安慰剂对照研究。

IF 1.7

Human psychopharmacology Pub Date : 2013-01-01 Epub Date: 2012-12-20 DOI: 10.1002/hup.2282

Ladan Kashani, Firoozeh Raisi, Sepideh Saroukhani, Hamid Sohrabi, Amirhossein Modabbernia, Abbas-Ali Nasehi, Amirhossein Jamshidi, Mandana Ashrafi, Parisa Mansouri, Padideh Ghaeli, Shahin Akhondzadeh

{"title":"Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study.","authors":"Ladan Kashani, Firoozeh Raisi, Sepideh Saroukhani, Hamid Sohrabi, Amirhossein Modabbernia, Abbas-Ali Nasehi, Amirhossein Jamshidi, Mandana Ashrafi, Parisa Mansouri, Padideh Ghaeli, Shahin Akhondzadeh","doi":"10.1002/hup.2282","DOIUrl":"https://doi.org/10.1002/hup.2282","url":null,"abstract":"Objective: Saffron (Crocus sativus L.) has shown beneficial aphrodisiac effects in some animal and human studies. The aim of the present study was to assess the safety and efficacy of saffron on selective serotonin reuptake inhibitor-induced sexual dysfunction in women.Methods: This was a randomized double-blind placebo-controlled study. Thirty-eight women with major depression who were stabilized on fluoxetine 40 mg/day for a minimum of 6 weeks and had experienced subjective feeling of sexual dysfunction entered the study. The patients were randomly assigned to saffron (30 mg/daily) or placebo for 4 weeks. Measurement was performed at baseline, week 2, and week 4 using the Female Sexual Function Index (FSFI). Side effects were systematically recorded.Results: Thirty-four women had at least one post-baseline measurement and completed the study. Two-factor repeated measure analysis of variance showed significant effect of time × treatment interaction [Greenhouse-Geisser's corrected: F(1.580, 50.567) = 5.366, p = 0.012] and treatment for FSFI total score [F(1, 32) = 4.243, p = 0.048]. At the end of the fourth week, patients in the saffron group had experienced significantly more improvement in total FSFI (p < 0.001), arousal (p = 0.028), lubrication (p = 0.035), and pain (p = 0.016) domains of FSFI but not in desire (p = 0.196), satisfaction (p = 0.206), and orgasm (p = 0.354) domains. Frequency of side effects was similar between the two groups.Conclusions: It seems saffron may safely and effectively improve some of the fluoxetine-induced sexual problems including arousal, lubrication, and pain.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"54-60"},"PeriodicalIF":1.7,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2282","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40204276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 109

Stress system changes associated with marijuana dependence may increase craving for alcohol and cocaine. 与大麻依赖相关的压力系统变化可能会增加对酒精和可卡因的渴望。

IF 1.7

Human psychopharmacology Pub Date : 2013-01-01 Epub Date: 2012-12-28 DOI: 10.1002/hup.2280

Helen C Fox, Keri L Tuit, Rajita Sinha

{"title":"Stress system changes associated with marijuana dependence may increase craving for alcohol and cocaine.","authors":"Helen C Fox, Keri L Tuit, Rajita Sinha","doi":"10.1002/hup.2280","DOIUrl":"https://doi.org/10.1002/hup.2280","url":null,"abstract":"Objective: To date, little research exists defining bio-behavioral adaptations associated with both marijuana abuse and risk of craving and relapse to other drugs of abuse during early abstinence.Method: Fifty-nine treatment-seeking individuals dependent on alcohol and cocaine were recruited. Thirty of these individuals were also marijuana (MJ) dependent; 29 were not. Twenty-six socially drinking healthy controls were also recruited. All participants were exposed to three 5-min guided imagery conditions (stress, alcohol/cocaine cue and relaxing), presented randomly, one per day across three consecutive days. Measures of craving, anxiety, heart rate, blood pressure, plasma adrenocorticotrophic hormone and cortisol were collected at baseline and subsequent recovery time points.Results: The MJ-dependent group showed increased basal anxiety ratings and cardiovascular output alongside enhanced alcohol craving and cocaine craving, and dampened cardiovascular response to stress and cue. They also demonstrated elevated cue-induced anxiety and stress-induced cortisol and adrenocorticotrophic hormone levels, which were not observed in the non-MJ-dependent group or controls. Cue-related alcohol craving and anxiety were both predictive of a shorter number of days to marijuana relapse following discharge from inpatient treatment.Conclusions: Findings provide some support for drug cross-sensitization in terms of motivational processes associated with stress-related and cue-related craving and relapse.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"40-53"},"PeriodicalIF":1.7,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2280","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40203523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36

Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. 口服非典型抗精神病药物改用长效注射利培酮对精神分裂症患者认知功能的影响。

IF 1.7

Human psychopharmacology Pub Date : 2009-10-01 DOI: 10.1002/hup.1057

Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Seung-Hyun Lee, Yo-Han Lee, Su-Jin Yang, Jin-Sang Yoon

{"title":"Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.","authors":"Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Seung-Hyun Lee, Yo-Han Lee, Su-Jin Yang, Jin-Sang Yoon","doi":"10.1002/hup.1057","DOIUrl":"https://doi.org/10.1002/hup.1057","url":null,"abstract":"Objective: To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia.Methods: Thirty-six patients with schizophrenia treated with oral AAPs participated in this open-label, 26-week study. Cognitive functions were measured at baseline and at 12 and 26 weeks. The secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS), Social and Occupational Functioning Assessment Scale (SOFAS), Scale for Unawareness of Mental Disorder (SUMD), and measurements for extrapyramidal symptoms.Results: Significant improvements in cognitive function were observed in the backward Digit Span Test, Verbal Learning Test, Wisconsin Card Sorting Test, correct responses on the Continuous Performance Test, and Trail Making Test part B following a switch to LAIR. Scores on the PANSS, SOFAS, SUMD, and the Simpson-Angus Rating Scale also improved significantly. Most improvements in neurocognitive function were not correlated with clinical measures. Weight gain and hyperprolactinemia were the most common adverse events.Conclusions: Switching from oral AAPs to LAIR improved cognitive function including vigilance, verbal learning and memory, executive function, sustained attention, and visuomotor speed in patients with schizophrenia. It was also effective for improving psychotic symptoms, social functioning, and insight.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"565-73"},"PeriodicalIF":1.7,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.1057","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40045271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. 精神分裂症缓解:意大利对精神分裂症或分裂情感性障碍患者利培酮长效注射(RLAI)为期一年的前瞻性研究。

IF 1.7

Human psychopharmacology Pub Date : 2009-10-01 DOI: 10.1002/hup.1067

Alessandro Rossi, Anna Bagalà, Vincenzo Del Curatolo, Francesco Scapati, Micaela Maria Bernareggi, Maria Grazia Giustra

{"title":"Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.","authors":"Alessandro Rossi, Anna Bagalà, Vincenzo Del Curatolo, Francesco Scapati, Micaela Maria Bernareggi, Maria Grazia Giustra","doi":"10.1002/hup.1067","DOIUrl":"https://doi.org/10.1002/hup.1067","url":null,"abstract":"Objectives: To evaluate the maintenance of efficacy of risperidone long-acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors factors of remission according to psychopathological, psychosocial and subjective correlates.Methods: 52-week, open-label prospective trial in 347 stable patients switching directly to RLAI from any previous antipsychotic treatment.Results: One year of treatment was completed by 70% of patients. Positive and Negative Syndrome Scale (PANSS) total and subscale, Global Assessment of Functioning (GAF) and Clinical Global Impression (CGI) scores improved from baseline at each assessment visit (p < 0.001, p < 0.001 and p < 0.05, respectively). Drug Attitude Inventory 30 (DAI30) scores improved significantly from month 3 onwards. 32% of patients met sustained remission at week 52. In a logistic regression model less severe positive and negative PANSS scores at baseline predicted remission (p < 0.001). RLAI treatment was well tolerated: one-third of patients reported mild to moderate adverse events (AEs). Eleven patients (3.2%) discontinued treatment due to an AE. No significant weight gain (p = 0.093) was reported.Conclusions: RLAI treatment up to one year improved symptoms and global functioning versus baseline, indicating that an established and accepted antipsychotic therapy can enable patients with schizophrenia to achieve and maintain remission.","PeriodicalId":520641,"journal":{"name":"Human psychopharmacology","volume":" ","pages":"574-83"},"PeriodicalIF":1.7,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.1067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40045272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36

Current awareness in human psychopharmacology. 当前对人类精神药理学的认识。

IF 1.7

Human psychopharmacology Pub Date : 2008-07-01

引用次数: 0

Current awareness in human psychopharmacology. 当前对人类精神药理学的认识。

IF 1.7

Human psychopharmacology Pub Date : 2007-10-01

引用次数: 0

Current awareness in human psychopharmacology. 当前对人类精神药理学的认识。

IF 1.7

Human psychopharmacology Pub Date : 2007-08-01

引用次数: 0